Stratos Wealth Partners LTD. Purchases Shares of 3,350 MoonLake Immunotherapeutics (NASDAQ:MLTX)

Stratos Wealth Partners LTD. purchased a new stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 3,350 shares of the company’s stock, valued at approximately $202,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. UBS Group AG purchased a new position in shares of MoonLake Immunotherapeutics in the 2nd quarter worth approximately $387,000. FMR LLC purchased a new position in shares of MoonLake Immunotherapeutics in the 2nd quarter worth approximately $6,264,000. Millennium Management LLC purchased a new position in shares of MoonLake Immunotherapeutics in the 2nd quarter worth approximately $147,000. Citadel Advisors LLC purchased a new position in shares of MoonLake Immunotherapeutics in the 2nd quarter worth approximately $13,916,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of MoonLake Immunotherapeutics in the 2nd quarter worth approximately $4,439,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on MLTX shares. Wedbush restated an “outperform” rating and issued a $92.00 target price on shares of MoonLake Immunotherapeutics in a research note on Wednesday, March 13th. Wolfe Research started coverage on MoonLake Immunotherapeutics in a research note on Thursday, February 15th. They issued an “outperform” rating and a $77.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $66.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, April 9th. William Blair reaffirmed an “outperform” rating and issued a $92.00 price target on shares of MoonLake Immunotherapeutics in a report on Monday, February 26th. Finally, The Goldman Sachs Group began coverage on shares of MoonLake Immunotherapeutics in a report on Tuesday, April 2nd. They issued a “neutral” rating and a $62.00 price target on the stock. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics has an average rating of “Moderate Buy” and an average target price of $74.46.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $62.43, for a total transaction of $624,300.00. Following the sale, the insider now owns 130,071 shares of the company’s stock, valued at approximately $8,120,332.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Da Silva Jorge Santos sold 4,740 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $55.89, for a total value of $264,918.60. Following the transaction, the chief executive officer now owns 2,982,814 shares of the company’s stock, valued at $166,709,474.46. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Kristian Reich sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $62.43, for a total transaction of $624,300.00. Following the completion of the transaction, the insider now directly owns 130,071 shares in the company, valued at approximately $8,120,332.53. The disclosure for this sale can be found here. Insiders have sold 166,981 shares of company stock valued at $9,490,674 in the last 90 days. 15.27% of the stock is currently owned by company insiders.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX stock opened at $43.50 on Wednesday. The company’s fifty day simple moving average is $51.27 and its two-hundred day simple moving average is $52.50. MoonLake Immunotherapeutics has a 1 year low of $18.43 and a 1 year high of $64.98. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of -57.24 and a beta of 1.20.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Thursday, February 29th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.11. Equities research analysts anticipate that MoonLake Immunotherapeutics will post -1.11 EPS for the current year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.